Trethera Corp
TRE-515, a small molecule therapeutic for autoimmune, oncology, and neuroinflammatory diseases
- Sector
- Biotech
- Headquarters
- Sherman Oaks, CA
- Founded
- 2013
- Latest Form D
- $250K, May 2025
- Total capital
- $39.1M
- Federal grants
- $10.8M
- 16 awards · 2022–2025
- 16× sector median 1 award
- Private capital raised
- $28.3M
- 8 Form D · last May 2025
- 18 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to enable further clinical advancement in non-small-cell lung cancer$407K
- Federal grantHealth and Human S · Phase II · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease$905K
- Federal grantHealth and Human S · Phase II · Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors$1.1M
- Federal grantHealth and Human S · Phase II · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus$995K
- Federal grantHealth and Human S · Phase II · Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)$1M
- Private capital raisedForm D · SEC · 8th filing$250K
- Federal grantHealth and Human S · Phase II · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis$622K
- Private capital raisedForm D · SEC · 7th filing$3.8M
- Private capital raisedForm D · SEC · 6th filing$3.3M
- Private capital raisedForm D · SEC · 5th filing$581K
- Private capital raisedForm D · SEC · 4th filing$8.1M
- Private capital raisedForm D · SEC · 3rd filing$4.2M
- Private capital raisedForm D · SEC · 2nd filing$7.4M
- Private capital raisedForm D · SEC · 1st filing$800K
Show 10 earlier federal awards
- Federal grantHealth and Human S · Phase I · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)$297K
- Federal grantHealth and Human S · Phase II · Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)$1.1M
- Federal grantHealth and Human S · Phase II · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types$697K
- Federal grantHealth and Human S · Phase I · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus$306K
- Federal grantHealth and Human S · Phase II · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis$616K
- Federal grantHealth and Human S · Phase I · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease$395K
- Federal grantHealth and Human S · Phase I · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)$304K
- Federal grantHealth and Human S · Phase I · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus$305K
- Federal grantHealth and Human S · Phase II · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types$1.3M
- Federal grantHealth and Human S · Phase II · Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis$368K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Caius B. RaduDirectorNamed in SEC Form D filings
- Carl W. McKinzieExecutive Officer, DirectorNamed in SEC Form D filings
- Jean B. deKernionDirectorNamed in SEC Form D filings
- Johanna HolldackExecutive Officer, DirectorNamed in SEC Form D filings
- Johannes CzerninDirectorNamed in SEC Form D filings
- John W. StrettonExecutive OfficerNamed in SEC Form D filings
Show all 14 people
- Kenneth A. Schultz, M.D.Executive Officer, DirectorNamed in SEC Form D filings
- Laurent Boyd DuboisDirectorNamed in SEC Form D filings
- Louis L. GondaDirectorNamed in SEC Form D filings
- Lynne W. RollinsExecutive OfficerNamed in SEC Form D filings
- Nathan W. MataExecutive OfficerNamed in SEC Form D filings
- Owen L. Witte, M.D.DirectorNamed in SEC Form D filings
- R. Boyd QuinnellDirectorNamed in SEC Form D filings
- Timothy L. Donahue, M.D.DirectorNamed in SEC Form D filings
What it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Related companies, and why
- GelMEDIX, Inc.Similar federal contract value in Biotech · null in contracts
- Lead Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- AptamiR Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Vascugen, Inc.Similar federal contract value in Biotech · null in contracts
- Araceli Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- Enable MedicineSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .